Provided are benzimidazole derivatives of the general formula (I), where the variables are as described in the specification. A preferred compound is 2-methyl-1-{ [2-methyl-3-(trifluoromethyl)phenyllmethyl} -6-( 4-morpholinyl)-1H-benzimidazole-4-carboxylic acid. The compounds can inhibit members of the phosphoinositide 3’ OH kinase (PI3K) family such as, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Further provided is the use of the compounds in the treatment of various disease states. A preferred use of the compounds is in the treatment of cancer.